Failure in pivotal PhIII brain cancer trial drags Israel's VBL Therapeutics down
VBL Therapeutics $VBLT is in crisis mode this morning after it announced that its lead drug flunked a Phase III study in brain cancer. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
